November 28, 2017

Exhibit 10.7

000 Xxxxxxxx Xxxx, Xxxxx 000

Xxxx Xxxxxx, XX 00000

November 28, 2017

Wake Forest University Health Sciences
Xxxxxxx Xxxxxx Xxxxxxxxx
Xxxxxxx-Xxxxx, Xxxxx Xxxxxxxx 00000
Attention: Chief Innovation Officer

Ladies and Gentlemen:

Reference is made to:

(i) that certain License Agreement dated as of November 30, 2016 (the “Agreement”), by and among Chondrial Therapeutics IP Holdings, LLC (f/k/a Chondrial Therapeutics, LLC) and Wake Forest University Health Sciences.

By their signatures below and for good and valuable consideration, the parties hereby acknowledge and agree as follows:

1. Chondrial Party.

Chondrial Therapeutics IP Holdings, LLC (f/k/a Chondrial Therapeutics, LLC), having its principal offices at 0000 Xxxx 00^xx Xxxxxx, Xxxxxxxxxxxx, Xxxxxxx 00000 was listed in error as a party to the Agreement. The proper and full name and address of the Chondrial entity that is a party to the Agreement is Chondrial Therapeutics IP, LLC, a Delaware Limited Liability Company, having its principal offices at 000 Xxxxxxxx Xxxx, Xxxxx 000, Xxxx Xxxxxx, XX 00000.

Accordingly, the Agreement is hereby amended as of the date hereof to replace “Chondrial Therapeutics IP Holdings, LLC (f/k/a Chondrial Therapeutics, LLC), having its principal offices at 0000 Xxxx 00^xx Xxxxxx, Xxxxxxxxxxxx, Xxxxxxx 00000” with “Chondrial Therapeutics IP, LLC, a Delaware Limited Liability Company having its principal offices at 000 Xxxxxxxx Xxxx, Xxxxx 000, Xxxx Xxxxxx, XX 00000.”

2. Effect.

Except as amended hereby, the Agreement shall remain in full force and effect.

November 28, 2017
Page 2 of 2

3. No Waiver.

This Letter Amendment is effective only in the specific instance and for the specific purpose for which it is executed and shall not be considered a waiver or agreement to amend as to any provision of the Agreement in the future.

4. Counterparts.

This Letter Amendment may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., xxx.xxxxxxxx.xxx) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

Very truly yours,

Chondrial Therapeutics IP, LLC

By: /s/ Xxxxxxxx X. Johansson______________
Name: Xxxxxxxx X. Xxxxxxxxx
Title: Vice President of Regulatory Affairs and Counsel

ACCEPTED AND AGREED TO

as of the date first above written:

Wake Forest University Health Sciences

By: /s/ Xxxx Tomlinson__________
Name: Xxxx Xxxxxxxxx, X.Xx., PhD
Title: Chief Innovation Officer